Stelara (ustekinumab) is an injectable medication that belongs to a class called interleukin antagonists. It's used for treating adults and certain children with autoimmune conditions including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. For the most part, Stelara (ustekinumab) is given under the skin either at a clinic or at home. Side effects include inflammation of the nasal passages, headache, and feeling tired.
Moderate-to-severe plaque psoriasis (Ps) in adults and children ages 6 years and older
Psoriatic arthritis (PsA) in adults and children ages 6 years and older
Moderate-to-severe Crohn's disease (CD) in adults
Moderate-to-severe ulcerative colitis (UC) in adults
Stelara (ustekinumab) is an interleukin antagonist. It blocks proteins in your immune system called interleukin-12 (IL-12) and interleukin-23 (IL-23) from working. This helps to lower inflammation and treat symptoms caused by autoimmune conditions.
Source: DailyMed
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
More common
Body aches or pain
chills
cough producing mucus
difficulty with breathing
ear congestion
headache
hoarseness
itching of the vagina or genitals
loss of voice
lower back or side pain
painful or difficult urination
runny or stuffy nose
stomach pain
thick, white vaginal discharge with mild or no odor
tightness in the chest
unusual tiredness or weakness
Less common
Bladder pain
bloody or cloudy urine
burning feeling while urinating
dizziness
frequent urge to urinate
itching skin
lower back or side pain
pain or tenderness around the eyes and cheekbones
vomiting
Rare
Blurred or loss of vision
clear or bloody discharge from the nipple
confusion
dimpling of the breast skin
disturbed color perception
double vision
halos around lights
inverted nipple
itching, pain, redness, swelling, tenderness, or warmth on the skin
lump in the breast or under the arm
night blindness
overbright appearance of lights
persistent crusting or scaling of the nipple
redness or swelling of the breast
seizures
sore on the skin of the breast that does not heal
tunnel vision
Incidence not known
difficulty with swallowing
fast heartbeat
general feeling of tiredness or weakness
hives or welts, skin rash
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
rapid breathing
redness of the skin
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Muscle aches
Less common
Back pain
bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
difficulty with moving
joint pain or swelling
muscle cramps, pain, or stiffness
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Isn't injected as often as other similar medications
Comes as a prefilled syringe for easier home administration
Can be stored at room temperature up to
Can be used in children as young as 6 years old
Can weaken your immune system and raise your risk of infection
Potential to cause serious allergic reactions
For CD and UC, the first dose must be given as an IV infusion
Can't receive live vaccines while taking this medication
Mark your injection dates on a calendar. Stelara (ustekinumab) isn't injected that often, so it can be hard to remember when your doses are scheduled.
Inject Stelara (ustekinumab) into your stomach area, buttocks, thighs, or outer area of the upper arm. Rotate the site of injection with each dose to avoid any irritation.
Let your provider know if you have a latex allergy. The needle cover of the Stelara (ustekinumab) prefilled syringe contains latex.
Make sure you know how to properly inject Stelara (ustekinumab). Read the instructions for use to help you. Ask your provider or pharmacist if you have further questions.
Because Stelara (ustekinumab) can potentially weaken your immune system, it raises your risk for an infection. Let your provider know right away if you experience symptoms such as fever, chills, muscle aches, diarrhea, or fatigue.
Store Stelara (ustekinumab) in its original container in the refrigerator. But it can also be left at room temperature up to 30°C (86°F) for up to 30 days as long as it remains in the original carton. After that, it should be thrown away. Once Stelara (ustekinumab) has warmed up to room temperature, don't put it back in the fridge.
Stelara (ustekinumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Active, chronic, or recurrent infection | Taking other medications that weaken your immune system | Having certain conditions that raise risk of infection
Stelara (ustekinumab) can raise your risk of infections. Serious infections are more common in people taking other immunosuppressant medications and people with certain conditions. Let your provider know your past medical history before starting Stelara (ustekinumab), especially if you've ever had tuberculosis (TB) or certain viral infections. Also tell your provider if you have symptoms of an infection including fever, chills, muscle aches, diarrhea, or feeling very tired. If you develop a serious infection while taking Stelara (ustekinumab) you might have to stop the medication.
Risk factors: Lighter skin color | Older adults | Certain medical conditions | History of skin cancer
Stelara (ustekinumab) weakens your immune system and can raise your risk of certain cancers, especially skin cancer. Some cases of skin cancer were seen in people who already had a higher risk of developing skin cancer. Let your provider know if you have a history of skin cancer. Monitor your body for new skin growths and changes to your skin.
Posterior reversible encephalopathy syndrome (PRES) is a very rare side effect of Stelara (ustekinumab). Symptoms can appear anytime during treatment, ranging from within a few days and even up to a year or longer after your first dose. Let your provider know if you have any symptoms like headache, confusion, visual changes, and seizures.
You can receive non-live or inactivated vaccines while you're taking Stelara (ustekinumab), but your body might respond differently. Avoid getting live vaccines while you're taking Stelara (ustekinumab). Doing so might cause you to become sick. Make sure your shots are up to date before starting this medication.
There have been reports of people experiencing swelling in the lungs while taking Stelara (ustekinumab). Symptoms like coughing and trouble breathing were seen after one to three doses of the medication. In some cases, it can become serious and lead to hospitalization. Let your provider know if you're having symptoms so you can be treated right away.
Plaque psoriasis
Adults:
Weight 220 lbs or less: The typical dose is 45 mg injected under the skin once, then another 45 mg four weeks later. After the second dose, 45 mg is injected every 12 weeks.
Weight more than 220 lbs: The typical dose is 90 mg injected under the skin once, then another 90 mg four weeks later. After the second dose, 90 mg is injected every 12 weeks.
Children ages 6 to under 18 years:
Weight less than 132 lbs: The typical dose is 0.75 mg/kg of body weight injected under the skin once, then another 0.75 mg/kg four weeks later. After the second dose, 0.75 mg/kg is injected every 12 weeks.
Weight of 132 lbs to 220 lbs: The typical dose is 45 mg injected under the skin once, then another 45 mg four weeks later. After the second dose, 45 mg is injected every 12 weeks.
Weight more than 220 lbs: The typical dose is 90 mg injected under the skin once, then another 90 mg four weeks later. After the second dose, 90 mg is injected every 12 weeks.
Psoriatic arthritis
Adults:
Psoriatic arthritis only: The typical dose is 45 mg injected under the skin once, then another 45 mg four weeks later. After the second dose, 45 mg is injected every 12 weeks.
Psoriatic arthritis with plaque psoriasis and weighing more than 220 lbs: The typical dose is 90 mg injected under the skin once, then another 90 mg four weeks later. After the second dose, 90 mg is injected every 12 weeks.
Children ages 6 to under 18 years:
Weight less than 132 lbs: The typical dose is 0.75 mg/kg of body weight injected under the skin once, then another 0.75 mg/kg four weeks later. After the second dose, 0.75 mg/kg is injected every 12 weeks.
Weight of 132 lbs or more: The typical dose is 45 mg injected under the skin once, then another 45 mg four weeks later. After the second dose, 45 mg is injected every 12 weeks.
Psoriatic arthritis with plaque psoriasis and weighing more than 220 lbs: The typical dose is 90 mg injected under the skin once, then another 90 mg four weeks later. After the second dose, 90 mg is injected every 12 weeks.
Crohn's disease and ulcerative colitis:
Adults: The typical dose is 260 mg to 520 mg infusion into the veins (intravenous, IV) once, then 90 mg under the skin every 8 weeks.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Moderate-to-severe plaque psoriasis (Ps) in adults and children ages 6 years and older
Psoriatic arthritis (PsA) in adults and children ages 6 years and older
Moderate-to-severe Crohn's disease (CD) in adults
Moderate-to-severe ulcerative colitis (UC) in adults
Moderate-to-severe plaque psoriasis
Psoriatic arthritis
Moderate-to-severe Crohn's disease
Rheumatoid arthritis (RA) - adults only
Juvenile idiopathic arthritis (JIA) - people age 2 and older
Psoriatic arthritis (PsA) - adults only
Ankylosing spondylitis (AS) - adults only
Crohn's disease (CD) - people age 6 and older
Ulcerative colitis (UC) - people age 5 and older
Plaque psoriasis - adults only
Hidradenitis suppurativa (HS) - people age 12 and older
Uveitis - people age 2 and older
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Aggeletopoulou, I., et al. (2018). Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World Journal of Gastroenterology.
American College of Allergy, Asthma & Immunology. (n.d.). Latex allergy.
Feagan, B. G., et al. (2016). Ustekinumab as induction and maintenance therapy for Crohn’s disease. The New England Journal of Medicine.
Janssen Biotech, Inc. (2020). Getting comfortable with taking Stelara®.
Janssen Biotech, Inc. (2024). Stelara- ustekinumab injection, solution [package insert]. DailyMed.
Sands, B. E., et al. (2019). Ustekinumab as induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine.
Sudulagunta, S. R., et al. (2017). Posterior reversible encephalopathy syndrome (PRES). Oxford Medical Case Reports.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.